RxDoctor Payments DataLook up a doctor →

Wendy Lee, MD

Ophthalmic Plastic and Reconstructive Surgery · Miami, FLNPI 1306979620

Payments from drug & device makers

$615,780in general payments, 2019–2025

Across 582 payments — averaging $1058.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$293K
  • Galderma Laboratories, L.p.$130K
  • Mallinckrodt Enterprises LLC$75K
  • Amgen$34K
  • Mallinckrodt Hospital Products Inc.$24K
  • Argenx US, Inc.$20K
  • plus $41K from 24 others

What the payments were for

  • Consulting fees$184,04430%
  • Speaking & faculty fees$344,98756%
  • Travel & lodging$65,17611%
  • Food & beverage$21,5513%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$615,780 in reported general payments places this provider in the 90th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.

See all ophthalmic plastic and reconstructive surgery providers in Florida

Medicare billing

Part B allowed, 2024
$66,286
Medicare patients
175
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin11$941,716
ErythromycinErythromycin Base61$634
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha19$211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$23,640$941,71611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.

Other ophthalmic plastic and reconstructive surgery in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →